Preview

Вопросы гематологии/онкологии и иммунопатологии в педиатрии

Расширенный поиск

Прогностические маркеры лимфобластной лимфомы

https://doi.org/10.24287/1726-1708-2020-19-4-198-204

Полный текст:

Аннотация

Лимфобластная лимфома (ЛБЛ) – вторая по частоте встречаемости неходжкинская лимфома у детей. Согласно современным представлениям, ЛБЛ и острый лимфобластный лейкоз (ОЛЛ) рассматривают как проявления одного и того же заболевания, учитывая сходный морфологический субстрат опухоли – Т- и В-лимфобласты. Стандартом терапии ЛБЛ в настоящее время являются ОЛЛ-подобные риск-адаптированные протоколы лечения, позволяющие добиться показателей общей и бессобытийной выживаемости, достигающие 80–90%. Разделение на группы риска основано на стадии заболевания и ответе на терапию индукции. Однако проблема рецидивов/ рефрактерного течения заболевания остается серьезной ввиду отсутствия достаточно эффективных терапевтических опций. На сегодняшний день имеется достаточное количество клинических данных, достоверно показывающих, что ряд молекулярно-биологических факторов может быть использован для создания новой системы стратификации на группы риска пациентов с ЛБЛ. Настоящий обзор посвящен анализу различных факторов, которые могут быть ответственны за прогноз ЛБЛ у детей.

Об авторах

Е. В. Волчков
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия

Волчков Егор Васильевич, лаборант-исследователь отдела исследования лимфом

117997, Москва, ул. Саморы Машела, 1 



Ю. В. Ольшанская
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия
Москва


Н. В. Мякова
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия
Москва


Список литературы

1. Arber D., Orazi A., Hasserjian R., Thiele J., Borowitz M.J., Le Beau M.M., et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127 (20): 2391–405. DOI: 10.1182/blood-2016-03-643544

2. Dores G., Devesa S., Curtis R., Linet M.S., Morton L.M., et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood 2012; 119 (1): 34–43. DOI: 10.1182/blood-2011-04-347872

3. Sant M., Allemani C., Tereanu C., De Angelis R., Capocaccia R., Visser O., et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116 (19): 3724–34. DOI: 10.1182/blood-2010-05-282632

4. Burkhardt B., Zimmerman M., Oschlies I., Niggli F., Mann G., Parwaresch R., et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005; 131 (1): 39–49. DOI: 10.1111/j.1365-2141.2005.05735.x

5. Oschlies I., Burkhardt B., Salaverria I., Rosenwald A., d'Amore E.S.G., Szczepanowski M., et al. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica 2011; 96 (2): 262–8. DOI: 10.3324/haematol.2010.030809

6. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Lyon. IARC. 2008.

7. Reiter A., Schrappe M., Ludwig W., Tiemann M., Parwaresch R., Zimmermann M., et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000; 95 (2): 416–21.

8. Landmann E., Burkhardt B., Zimmermann M., Meyer U., Woessmann W., Klapper W., et al. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica 2017; 102 (12): 2086–96. DOI: 10.3324/haematol.2015.139162

9. Sandlund J., Pui C.H., Zhou Y., Behm F.G., Onciu M., Razzouk B.I., et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia 2009; 23 (6): 1127–30. DOI: 10.1038/leu.2008.400

10. Abromowitch M., Termuhlen A., Chang M., High-Dose Methotrexate and Early Intensification of Therapy Do Not Improve 3 Year EFS in Children and Adolescents with Disseminated Lymphoblastic Lymphoma. Results of the Randomized Arms of COG A5971. Blood 2008; 112 (11): 3610. DOI: 10.1182/blood.V112.11.3610.3610

11. Burkhardt B., Woessmann W., Zimmermann M., Kontny U., Vormoor J., Doerffel W., et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 2006; 24 (3): 491–9. DOI: 10.1200/JCO.2005.02.2707

12. Burkhardt B., Reiter A., Landmann E., Lang P., Lassay L., Dickerhoff R., et al. Poor Outcome for Children and Adolescents With Progressive Disease or Relapse of Lymphoblastic Lymphoma: A Report From the Berlin-Frankfurt-Muenster Group. J Clin Oncol 2009; 27 (20): 3363–9. DOI: 10.1200/JCO.2008.19.3367

13. Murphy S. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980; 7 (3): 332–9.

14. Tubergen D., Krailo M., Meadows A., Rosenstock J., Kadin M., Morse M., et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. J Clin Oncol 1995; 13 (6): 1368– 76. DOI: 10.1200/JCO.1995.13.6.1368

15. Burkhardt B., Oschlies I., Klapper W., Zimmermann M., Woessmann W., Meinhardt A., et al. Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia 2011; 25 (1): 153–60. DOI: 10.1038/leu.2010.245

16. Uyttebroeck A., Suciu S., Laureys G., Robert A., Pacquement H., Ferster A., et al. Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer 2008; 44 (6): 840–6. DOI: 10.1016/j.ejca.2008.02.011

17. Sandlund J., Guillerman R., Perkins S., Pinkerton C.R., Rosolen A., Patte C., et al. International Pediatric Non-Hodgkin Lymphoma Response Criteria. J Clin Oncol 2015; 33 (18): 2106–11. DOI: 10.1200/JCO.2014.59.0745

18. Coustan-Smith E., Sandlund J., Perkins S., Chen H., Chang M., Abromowitch M., et al. Minimal Disseminated Disease in Childhood T-Cell Lymphoblastic Lymphoma: A Report From the Children's Oncology Group. J Clin Oncol 2009; 27: 3533–9. DOI: 10.1200/JCO.2008.21.1318

19. Stark B., Avigad S., Luria D., Manor S., Reshef-Ronen T., Avrahami G., et al. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR). Pediatr Blood Cancer 2009; 52 (1): 20–5. DOI: 10.1002/pbc.21823

20. Callens C., Baleydier F., Lengline E., Abdelali R.B., Petit A., Villarese P., et al. Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol 2012; 30 (16): 1966– 73. DOI: 10.1200/JCO.2011.39.7661

21. Mussolin L., Buldini B., Lovisa F., Carraro E., Disarò S., Nigro L.L., et al. Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience. Pediatr Blood Cancer 2015; 62 (11): 1906–13. DOI: 10.1002/pbc.25607

22. Thastrup M., Marquart H., Levinsen M., Grell K., Abrahamsson J., Albertsen B.K., et al. Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study. Leukemia 2020; 34 (2): 336– 46. DOI: 10.1038/s41375-019-0570-1

23. Popov A., Henze G., Verzhbitskaya T., Roumiantseva J., Lagoyko S., Khlebnikova O., et al. Absolute count of leukemic blasts in cerebrospinal fluid as detected by flow cytometry is a relevant prognostic factor in children with acute lymphoblastic leukemia. J Cancer Res Clin Oncol 2019; 145 (5): 1331–9. DOI: 10.1007/s00432-019-02886-3

24. Brüggemann M., Schrauder A., Raff T., Pfeifer H., Dworzak M., Ottman O.G., et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010; 24 (3): 521–35. DOI: 10.1038/leu.2009.268

25. Brüggemann M., Kotrová M., Knecht H., Bartram J., Boudjogrha M., Bystry V., et al. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia 2019; 33 (9): 2241–53. DOI: 10.1038/s41375-019-0496-7

26. Комков А.Ю., Мирошниченкова А.М., Ольшанская Ю.В., Мякова Н.В., Дьяконова Ю.Ю., Минервина А.А. и др. Детекция перестроек иммуноглобулиновых генов при острых лимфобластных лейкозах с использованием высокопроизводительного секвенирования нового поколения. Гематология и трансфузиология 2016; 61 (4): 200-204. DOI: 10.18821/0234-5730-2016-61-4-200-204

27. Komkov A., Miroshnichenkova A., Nugmanov G., Popov A., Pogorelyy M., Zapletalova E., et al. High-throughput sequencing of T-cell receptor alpha chain clonal rearrangements at the DNA level in lymphoid malignancies. Br J Haematol 2020; 188 (5): 723–31. DOI: 10.1111/bjh.16230

28. Patel J., Smith L., Anderson J., Abromowitch M., Campana D., Jacobsen J., et al. The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children's Oncology Group report. Br J Haematol 2012; 159 (4): 454– 61. DOI: 10.1111/bjh.12042

29. Oschlies I., Burkhardt B., ChassagneClement C., d'Amore E.S., Hansson U., Hebeda K., et al. Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel. Am J Surg Pathol 2011; 35 (6): 836–44. DOI: 10.1097/PAS.0b013e318213e90e

30. Gerr H., Zimmermann M., Schrappe M., Dworzak M., Ludwig W.-D., Bradtke J., et al. Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. Br J Haematol 2010; 149 (1): 84–92. DOI: 10.1111/j.1365-2141.2009.08058.x

31. Olshanskaya Y., Kazakova A., Tsaur G., Zerkalenkova E., Soldatkina O., Aprelova E., et al. Clinical significance of cytogenetic changes in childhood T-cell acute lymphoblastic leukemia: results of the multicenter group Moscow-Berlin (MB). Leuk Lymphoma 2019; 60 (2): 426–32. DOI: 10.1080/10428194.2018.1485904

32. Aifantis I., Raetz E., Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008; 8 (5): 380–90. DOI: 10.1038/nri2304

33. Park M., Taki T., Oda M. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol 2009; 145 (2): 198–206. DOI: 10.1111/j.1365-2141.2009.07607.x

34. Burkhardt B., Hermiston M. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities. Br J Haematol 2019; 185 (6): 1158–70. DOI: 10.1111/bjh.15793

35. Bonn B., Rohde M., Zimmermann M., Dworzak M., Ludwig W.-D., Bradtke J., et al. Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood 2013; 121 (16): 3153–60. DOI: 10.1182/blood-2012-12-474148

36. Trinquand A., Tanguy-Schmidt A., Ben Abdelali R., Lambert J., Beldjord K., Lengliné E., et al. Toward a NOTCH1/FBXW7/ RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol 2013; 31 (34): 4333– 42. DOI: 10.1200/JCO.2012.48.5292

37. Petit A., Trinquand A., Chevret S., Ballerini P., Cayuela J.-M., Grardel N., et al. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. Blood 2018; 131 (3): 289–300. DOI: 10.1182/blood-2017-04-778829

38. Moorman A., Enshaei A., Schwab C., Wade R., Chilton L., Elliott A., et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood 2014; 124 (9): 1434–44. DOI: 10.1182/blood-2014-03- 562918

39. Stanulla M., Dagdan E., Zaliova M., Möricke A., Palmi C., Cazzaniga G., et al. IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. J Clin Oncol 2018; 36 (12): 1240–9. DOI: 10.1200/JCO.2017.74.3617

40. Balbach S., Makarova O., Bonn B., Zimmermann M., Rohde M., Oschlies I., et al. Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia. Leukemia 2016; 30 (4): 970–3. DOI: 10.1038/leu.2015.203

41. ClinicalTrials.gov Identifier: NCT04043494

42. O'Neil J., Grim J., Strack P., Rao S., Tibbitts D., Winter C., et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007; 204 (8): 1813–24. DOI: 10.1084/jem.20070876

43. Oswald F., Rodriguez P., Giaimo B., Antonello Z.A., Mira L., Mittler G., et al. A phospho-dependent mechanism involving NCoR and KMT2D controls a permissive chromatin state at Notch target genes. Nucleic Acids Res 2016; 44 (10): 4703–20. DOI: 10.1093/nar/gkw105

44. Palomero T., Dominguez M., Ferrando A. The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia. Cell Cycle 2008; 7 (8): 965–70. DOI: 10.4161/cc.7.8.5753

45. Petit A., Trinquand A., Chevret S. Oncogenetic Risk Classification Based on NOTCH1/FBXW7/RAS/PTEN Mutation Profiles Improves Outcome Prediction in Pediatric T-Cell Acute Lymphoblastic Leukemia, Treated According the Fralle 2000 T Guidelines. Blood 2016; 128 (22): 1083. DOI: 10.1182/blood.V128.22.1083.1083

46. Irving J., Matheson E., Minto L., Blair H., Case M., Halsey C.,et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood 2014; 124 (23): 3420–30. DOI: 10.1182/blood-2014-04-531871

47. Burkhardt B., Bruch J., M Zimmermann M., Strauch K., Parwaresch R., Ludwig W.-D., et al. Loss of heterozygosity on chromosome 6q14–q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia 2006; 20 (8): 1422–9. DOI: 10.1038/sj.leu.2404275

48. Burkhardt B., Moericke A., Klapper W., Greene F., Salzburg J., Damm-Welk C., et al. Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leuk Lymphoma 2008; 49 (3): 451–61. DOI: 10.1080/10428190701824551

49. Yang Y., Hsiao C., Chen H., Lin K.-H., Jou S.-T., Chen J.-S., et al. Absence of biallelic TCRg deletion predicts induction failure and poorer outcomes in childhood T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer 2012; 58 (6): 846– 51. DOI: 10.1002/pbc.24021

50. Larish A., Dolan M., Casey T., Perkins J. Bilateral ovarian B-lineage lymphoblastic lymphoma with MLL gene rearrangement: a novel case in infancy. J Pediatr Hematol Oncol 2015; 37 (4): e215–7. DOI: 10.1097/MPH.0000000000000296

51. Boddu P., Yin C., Kanagal-Shamanna R., Tang G., Thakral B., Kadia T., et al. An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma. Case Rep Hematol 2017; 2017: 2413587. DOI: 10.1155/2017/2413587

52. Kubota-Tanaka M., Osumi T., Miura S., Tsujimoto H., , Imamura T., Nishimura A., et al. B-lymphoblastic lymphoma with TCF3-PBX1 fusion gene. Haematologica 2019; 104 (1): e35–37. DOI: 10.3324/haematol.2018.199885

53. Meyer J., Zhou D., Mason C., Downie J.M., Rodic V., Abromowitch M., et al. Genomic characterization of pediatric B-lymphoblastic lymphoma and B-lymphoblastic leukemia using formalin-fixed tissues. Pediatr Blood Cancer 2017; 64 (7). DOI: 10.1002/pbc.26363


Для цитирования:


Волчков Е.В., Ольшанская Ю.В., Мякова Н.В. Прогностические маркеры лимфобластной лимфомы. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2020;19(4):198-204. https://doi.org/10.24287/1726-1708-2020-19-4-198-204

For citation:


Volchkov E.V., Olshanskaya Yu.V., Myakova N.V. Prognostic markers of lymphoblastic lymphoma. Pediatric Hematology/Oncology and Immunopathology. 2020;19(4):198-204. (In Russ.) https://doi.org/10.24287/1726-1708-2020-19-4-198-204

Просмотров: 159


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-1708 (Print)
ISSN 2414-9314 (Online)